Key Takeaways
- • ARK Invest committed $20 million to Cellares' Series D funding round, which closed at $277 million total capitalization, positioning the cell therapy manufacturing platform alongside institutional investors including BlackRock, Eclipse, and T. Rowe Price.
- • Cellares' Cell Shuttle automated platform has demonstrated clinical validation: in April 2026, the company manufactured and delivered the first two GMP-compliant doses of rese-cel (Cabaletta Bio's CAR T cell therapy), both meeting all release specifications for patient infusion.
- • The company has secured major commercial commitments including a $380 million global manufacturing agreement with Bristol Myers Squibb and a 10-year commercial supply agreement with Cabaletta Bio, establishing capacity across the United States, Europe, and Japan targeting hundreds of thousands of annual patient treatments beginning in 2027.
- • Cellares operates a global manufacturing footprint spanning South San Francisco and Bridgewater, New Jersey, with additional facilities under development in Leiden (Netherlands) and Kashiwa City (Japan), addressing the critical bottleneck of scaling cell therapy production at industrial capacity.
- • Cathie Wood, ARK Invest's Founder and CIO, emphasized the investment thesis: "The science behind cell therapy is proven. The challenge now is manufacturing these life-saving treatments at the scale and cost required to meet patient demand."
Summary
ARK Invest announced a $20 million investment in Cellares' Series D funding round on June 9, 2026, bringing total Series D capitalization to $277 million. The financing round reflects institutional confidence in Cellares' automated cell therapy manufacturing platform at a critical inflection point for the industry. The round also included participation from BlackRock, Eclipse, and T. Rowe Price, signaling broad institutional support for the company's technology and commercial trajectory.
Cellares has positioned itself at the intersection of clinical validation and manufacturing scale-up. In April 2026, the company achieved a significant milestone by manufacturing and delivering the first two GMP-compliant doses of rese-cel, Cabaletta Bio's investigational CAR T cell therapy, using its proprietary Cell Shuttle automation platform. Both doses met all release specifications and were infused into patients on schedule, demonstrating that the company's technology can transition from development to commercial-grade production. This validation directly addresses the manufacturing bottleneck that has historically constrained cell therapy deployment at therapeutic scale.
The company's commercial pipeline strengthens the investment case. Cellares has secured a $380 million global manufacturing agreement with Bristol Myers Squibb, reserving commercial-scale manufacturing capacity across the United States, Europe, and Japan for BMS's cell therapy programs. Additionally, Cabaletta Bio executed a 10-year commercial supply agreement with Cellares, anchoring long-term demand and revenue visibility. These agreements demonstrate that major pharmaceutical players view Cellares' automated platform as a credible solution for scaling cell therapy production.
Infrastructure expansion underpins growth ambitions. Beyond existing facilities in South San Francisco and Bridgewater, New Jersey, Cellares is developing manufacturing sites in Leiden, the Netherlands, and Kashiwa City, Japan. This global network strategy targets commercial-scale production capacity for hundreds of thousands of patients annually beginning in 2027. The geographic diversification mitigates regulatory and supply chain risk while positioning the company for multinational pharmaceutical partnerships.
ARK Invest's participation reflects the fund's conviction thesis on cell therapy manufacturing as a systemic bottleneck solution. Per Cathie Wood, "The science behind cell therapy is proven. The challenge now is manufacturing these life-saving treatments at the scale and cost required to meet patient demand." For alternative investors and family offices, this investment signals that institutional venture capital continues to prioritize infrastructure enablers in high-growth therapeutic categories, particularly where manufacturing automation can unlock market expansion constrained by production capacity rather than clinical efficacy.
Cellares has positioned itself at the intersection of clinical validation and manufacturing scale-up. In April 2026, the company achieved a significant milestone by manufacturing and delivering the first two GMP-compliant doses of rese-cel, Cabaletta Bio's investigational CAR T cell therapy, using its proprietary Cell Shuttle automation platform. Both doses met all release specifications and were infused into patients on schedule, demonstrating that the company's technology can transition from development to commercial-grade production. This validation directly addresses the manufacturing bottleneck that has historically constrained cell therapy deployment at therapeutic scale.
The company's commercial pipeline strengthens the investment case. Cellares has secured a $380 million global manufacturing agreement with Bristol Myers Squibb, reserving commercial-scale manufacturing capacity across the United States, Europe, and Japan for BMS's cell therapy programs. Additionally, Cabaletta Bio executed a 10-year commercial supply agreement with Cellares, anchoring long-term demand and revenue visibility. These agreements demonstrate that major pharmaceutical players view Cellares' automated platform as a credible solution for scaling cell therapy production.
Infrastructure expansion underpins growth ambitions. Beyond existing facilities in South San Francisco and Bridgewater, New Jersey, Cellares is developing manufacturing sites in Leiden, the Netherlands, and Kashiwa City, Japan. This global network strategy targets commercial-scale production capacity for hundreds of thousands of patients annually beginning in 2027. The geographic diversification mitigates regulatory and supply chain risk while positioning the company for multinational pharmaceutical partnerships.
ARK Invest's participation reflects the fund's conviction thesis on cell therapy manufacturing as a systemic bottleneck solution. Per Cathie Wood, "The science behind cell therapy is proven. The challenge now is manufacturing these life-saving treatments at the scale and cost required to meet patient demand." For alternative investors and family offices, this investment signals that institutional venture capital continues to prioritize infrastructure enablers in high-growth therapeutic categories, particularly where manufacturing automation can unlock market expansion constrained by production capacity rather than clinical efficacy.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.